Effect of baseline HbA1c, renal function, age and glucose-lowering medication on hypoglycaemia in the EMPA-REG OUTCOME trial

被引：0
|
作者：
Duarte, J. [1 ]
Krarup, T. [2 ]
Kohler, S. [3 ]
Mattheus, M. [3 ]
George, J. [3 ]
Woerle, H. -J. [3 ]
Inzucchi, S. [4 ]
Zinman, B. [5 ,6 ]
机构：
[1] Hosp Egas Moniz, Ctr Hosp Lisboa Ocidental, Lisbon, Portugal
[2] Bispebjerg Hosp, Med Endokrinologisk Afd 1, Copenhagen, Denmark
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[4] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA
[5] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[6] Univ Toronto, Div Endocrinol, Toronto, ON, Canada
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
731
引用
收藏
页码：S348 / S348
页数：1
相关论文
共 50 条
  • [1] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME
    Whyte, M. B.
    Shah, S.
    McGovern, A.
    van Vlymen, J.
    Hinton, W.
    Munro, N.
    de Lusignan, S.
    DIABETIC MEDICINE, 2018, 35 : 95 - 96
  • [2] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME
    Inzucchi, S. E.
    Fitchett, D.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Woerle, H. J.
    Zinman, B.
    DIABETIC MEDICINE, 2018, 35 : 11 - 11
  • [3] Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial
    Fitchett, D.
    Inzucchi, S. E.
    Wanner, C.
    Mattheus, M.
    George, J. G.
    Woerle, H. J.
    Zinman, B.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 121 - 121
  • [4] Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular (CV) death with empagliflozin? Results from EMPA-REG OUTCOME
    Inzucchi, S. E.
    Fitchett, D.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Woerle, H. J.
    Zinman, B.
    DIABETOLOGIA, 2017, 60 : S425 - S425
  • [5] Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial
    Schernthaner, G.
    Schernthaner, G. -H.
    HERZ, 2016, 41 (03) : 208 - 216
  • [6] Reduction in Cardiovascular (CV) Death with Empagliflozin Is Consistent across Categories of Baseline HbA1c and Change in HbA1c: Results from EMPA-REG OUTCOME
    Inzucchi, Silvio E.
    Fitchett, David
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Woerle, Hans J.
    Zinman, Bernard
    DIABETES, 2017, 66 : A313 - A313
  • [7] Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from EMPA-REG OUTCOME
    Woerle, H. J.
    Fitchett, D.
    Inzucchi, S. E.
    Wanner, C.
    Mattheus, M.
    George, J. T.
    Zinman, B.
    DIABETOLOGIA, 2017, 60 : S426 - S426
  • [8] Impact of Changes in Glucose-Lowering Therapy on Analyses of Glycemic Control and Weight in EMPA-REG Outcome
    Schernthaner, Guntram
    Scheen, Andre
    Naderali, Ebrahim
    Johansen, Odd Erik
    Mattheus, Michaela
    Zinman, Bernard
    DIABETES, 2016, 65 : A294 - A295
  • [9] IMPACT OF CHANGES IN GLUCOSE-LOWERING THERAPY ON ANALYSES OF GLYCEMIC CONTROL AND WEIGHT IN EMPA-REG OUTCOME
    Lee, Dae Wook
    Schernthaner, Guntram
    Scheen, Andre
    Johansen, Odd Erik
    Zinman, Bernard
    JOURNAL OF HYPERTENSION, 2016, 34 : E519 - E519
  • [10] Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial
    Antonio Ceriello
    Anne Pernille Ofstad
    Isabella Zwiener
    Stefan Kaspers
    Jyothis George
    Antonio Nicolucci
    Cardiovascular Diabetology, 19
12345